91 related articles for article (PubMed ID: 22888961)
21. Hyaluronan expression in differentiated thyroid carcinoma.
Böhm J; Niskanen L; Tammi R; Tammi M; Eskelinen M; Pirinen R; Hollmen S; Alhava E; Kosma VM
J Pathol; 2002 Feb; 196(2):180-5. PubMed ID: 11793369
[TBL] [Abstract][Full Text] [Related]
22. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma.
Kim EY; Kim WG; Kim WB; Kim TY; Kim JM; Ryu JS; Hong SJ; Gong G; Shong YK
Clin Endocrinol (Oxf); 2009 Oct; 71(4):581-6. PubMed ID: 19222495
[TBL] [Abstract][Full Text] [Related]
23. [Analysis of surgical treatment of papillary thyroid carcinoma].
Zhang ZM; Li ZJ; Tang PZ; Xu ZG; An CM
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):779-82. PubMed ID: 22335912
[TBL] [Abstract][Full Text] [Related]
24. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
25. Completion thyroidectomy in 131 patients with differentiated thyroid carcinoma.
Scheumann GF; Seeliger H; Musholt TJ; Gimm O; Wegener G; Dralle H; Hundeshagen H; Pichlmayr R
Eur J Surg; 1996 Sep; 162(9):677-84. PubMed ID: 8908447
[TBL] [Abstract][Full Text] [Related]
26. Maspin in thyroid cancer: its relationship with p53 and clinical outcome.
Boltze C; Schneider-Stock R; Meyer F; Peters B; Quednow C; Hoang-Vu C; Roessner A
Oncol Rep; 2003; 10(6):1783-7. PubMed ID: 14534696
[TBL] [Abstract][Full Text] [Related]
27. CD147 expression as a significant prognostic factor in differentiated thyroid carcinoma.
Tan H; Ye K; Wang Z; Tang H
Transl Res; 2008 Sep; 152(3):143-9. PubMed ID: 18774544
[TBL] [Abstract][Full Text] [Related]
28. Papillary thyroid carcinoma: factors influencing recurrence and survival.
Toniato A; Boschin I; Casara D; Mazzarotto R; Rubello D; Pelizzo M
Ann Surg Oncol; 2008 May; 15(5):1518-22. PubMed ID: 18324441
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma.
Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY
Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695
[TBL] [Abstract][Full Text] [Related]
30. Expression and function of the novel proto-oncogene PBF in thyroid cancer: a new target for augmenting radioiodine uptake.
Smith VE; Franklyn JA; McCabe CJ
J Endocrinol; 2011 Aug; 210(2):157-63. PubMed ID: 21450804
[TBL] [Abstract][Full Text] [Related]
31. Papillary and follicular variant of papillary carcinoma of the thyroid: Initial presentation and response to therapy.
Burningham AR; Krishnan J; Davidson BJ; Ringel MD; Burman KD
Otolaryngol Head Neck Surg; 2005 Jun; 132(6):840-4. PubMed ID: 15944551
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of patients with insular carcinoma of the thyroid: the insular histotype is an independent predictor of poor prognosis.
Pellegriti G; Giuffrida D; Scollo C; Vigneri R; Regalbuto C; Squatrito S; Belfiore A
Cancer; 2002 Nov; 95(10):2076-85. PubMed ID: 12412160
[TBL] [Abstract][Full Text] [Related]
33. Predictors of outcome in patients with papillary thyroid carcinoma.
Kjellman P; Zedenius J; Lundell G; Bäckdahl M; Farnebo LO; Hamberger B; Larsson C; Wallin G
Eur J Surg Oncol; 2006 Apr; 32(3):345-52. PubMed ID: 16459050
[TBL] [Abstract][Full Text] [Related]
34. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas.
Lin JD; Huang MJ; Hsu BR; Chao TC; Hsueh C; Liu FH; Liou MJ; Weng HF
J Surg Oncol; 2002 May; 80(1):45-51. PubMed ID: 11967907
[TBL] [Abstract][Full Text] [Related]
35. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study.
Lundgren CI; Hall P; Dickman PW; Zedenius J
Cancer; 2006 Feb; 106(3):524-31. PubMed ID: 16369995
[TBL] [Abstract][Full Text] [Related]
36. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma.
Böhm JP; Niskanen LK; Pirinen RT; Kiraly K; Kellokoski JK; Moisio KI; Eskelinen MJ; Tulla HE; Hollmen S; Alhava EM; Kosma VM
J Pathol; 2000 Nov; 192(3):321-7. PubMed ID: 11054715
[TBL] [Abstract][Full Text] [Related]
37. Management and outcome of recurrent well-differentiated thyroid carcinoma.
Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging.
Lang BH; Lo CY; Chan WF; Lam KY; Wan KY
Ann Surg Oncol; 2007 Feb; 14(2):730-8. PubMed ID: 17103065
[TBL] [Abstract][Full Text] [Related]
39. Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas.
Müssig K; Wehrmann T; Dittmann H; Wehrmann M; Ueberberg B; Schulz S; Bares R; Petersenn S
Clin Endocrinol (Oxf); 2012 Jul; 77(1):139-45. PubMed ID: 22248072
[TBL] [Abstract][Full Text] [Related]
40. Papillary thyroid carcinoma: a multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system.
Salvesen H; Njølstad PR; Akslen LA; Albrektsen G; Søreide O; Varhaug JE
Eur J Surg; 1992; 158(11-12):583-9. PubMed ID: 1363062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
